9 Meters Biopharma, Inc. (NMTRQ) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
9 Meters Biopharma, Inc. (NMTRQ) trades at $0.0001 with AI Score 48/100 (Grade C). 9 Meters Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for rare digestive diseases and gastrointestinal disorders. Sector: Healthcare.
Price as of Jul 20, 2026 · Last analyzed: Jun 14, 2026Analyst Coverage for NMTRQ: NMTRQ does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates NMTRQ against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
NMTRQ: the 3 scored disciplines are evenly split. Dominant signal: Izzy Englander bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
9 Meters Biopharma, Inc. (NMTRQ) Healthcare & Pipeline Overview
9 Meters Biopharma, Inc. is a clinical-stage biopharmaceutical firm specializing in innovative therapies for rare digestive diseases, with a focus on unmet medical needs in gastrointestinal disorders, particularly through its lead candidate, Vurolenatide.
What Is the Investment Thesis for NMTRQ?
9 Meters Biopharma, Inc. operates in a niche segment of the biotechnology industry focused on rare digestive diseases, which presents unique growth opportunities. The company's lead candidate, Vurolenatide, is in Phase 3 trials, potentially positioning it for market entry should it receive regulatory approval. The market for treatments addressing short bowel syndrome and related gastrointestinal disorders is significant, with increasing awareness and demand for effective therapies. However, the company faces substantial risks, including its recent bankruptcy filing, which complicates its operational viability and future funding prospects. The outcome of ongoing clinical trials and the ability to secure partnerships or funding will be critical in determining the company’s future trajectory.
Based on FMP financials and quantitative analysis
NMTRQ Key Highlights
- Market Cap: $0.00B due to bankruptcy proceedings.
- ROE: -375.6%, indicating significant financial distress.
- Free Cash Flow: -$0.02B, reflecting ongoing operational challenges.
- Beta: 9.33, suggesting high volatility in stock performance.
- Dividend Yield: None, as the company does not currently distribute dividends.
Who Are NMTRQ's Competitors?
NMTRQ is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ALBO Albireo Pharma, Inc. | $44.15 | +0.00% | $916M | 71 |
| ADAPY Adaptimmune Therapeutics plc | $0.04 | -3.80% | $10.1M | 72 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.10 | +1.74% | $168M | 76 |
| CGEN Compugen Ltd. | $2.49 | +6.41% | $235M | 76 |
| NAGE Niagen Bioscience Inc | $3.49 | +3.56% | $278M | 69 |
| ADGI Adagio Therapeutics, Inc. | $4.64 | +0.87% | $506M | 71 |
| GNFTF Genfit S.A. | $10.75 | +0.00% | $539M | 73 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are NMTRQ's Key Strengths?
- Innovative pipeline with multiple drug candidates targeting rare diseases.
- Strong focus on unmet medical needs in gastrointestinal health.
- Established partnerships with other biopharmaceutical firms.
What Are NMTRQ's Weaknesses?
- Recent bankruptcy filing raises concerns about financial stability.
- Limited operational scale with only 10 employees.
- High volatility in stock performance due to market conditions.
What Could Drive NMTRQ Stock Higher?
- Phase 3 clinical trials for Vurolenatide, which could lead to potential market entry if successful.
- Potential licensing agreements that could provide additional funding or resources for development.
- Continued research and development efforts on NM-136 and NM-102, targeting obesity and autoimmune diseases.
What Are the Key Risks for NMTRQ?
- Financial instability due to the recent bankruptcy filing, impacting operations and funding.
- Regulatory hurdles that could delay or prevent approval of drug candidates.
- High competition in the biotechnology sector, which may hinder market penetration.
What Are the Growth Opportunities for NMTRQ?
- Growth opportunity 1: The market for short bowel syndrome treatments is projected to grow significantly, driven by increasing diagnosis rates and a growing patient population. As awareness of this debilitating condition rises, the demand for effective therapies like Vurolenatide could expand, potentially capturing a significant share of the market, which is estimated to exceed $1 billion by 2028.
- Growth opportunity 2: The obesity treatment market is experiencing rapid growth, with increasing prevalence rates globally. NM-136, the company's humanized monoclonal antibody, targets obesity and related metabolic disorders, which are becoming critical public health issues. This market is expected to reach over $30 billion by 2025, providing a substantial opportunity for 9 Meters Biopharma if clinical trials yield positive results.
- Growth opportunity 3: The development of NM-102, aimed at preventing antigen entry into systemic circulation, addresses a significant unmet need in various autoimmune and inflammatory conditions. As research in this area progresses, the potential for NM-102 to enter the market could tap into a lucrative segment, with the autoimmune disease market projected to reach $200 billion by 2025.
- Growth opportunity 4: NM-003, targeting acute graft versus host disease, represents an opportunity in the oncology and transplant sectors, where there is a high demand for effective preventative therapies. The market for graft versus host disease treatments is expected to grow as more patients undergo stem cell transplants, potentially reaching $1 billion by 2026.
- Growth opportunity 5: The partnership with Amunix and other licensing agreements could provide additional revenue streams and enhance the company's research capabilities. Collaborations in the biotechnology space are increasingly common, and successful partnerships can lead to accelerated development timelines and shared financial burdens, positioning 9 Meters Biopharma for future growth.
What Opportunities Does NMTRQ Have?
- Growing market for obesity and gastrointestinal disease treatments.
- Potential for successful partnerships to enhance research and development.
- Increasing demand for effective therapies in niche markets.
What Threats Does NMTRQ Face?
- Intense competition from other biotechnology firms.
- Regulatory challenges in drug approval processes.
- Market volatility impacting investor confidence and funding availability.
What Are NMTRQ's Competitive Advantages?
- Specialization in rare diseases provides a unique market position with less competition.
- Strong pipeline of innovative therapies targeting unmet medical needs.
- Established partnerships with reputable organizations enhance credibility and research capabilities.
- Intellectual property protections for proprietary drug candidates create barriers to entry.
- Clinical-stage advancements in drug development increase potential for future revenue streams.
What Does NMTRQ Do?
Founded with the mission to address significant gaps in treatment for rare digestive diseases, 9 Meters Biopharma, Inc. has positioned itself as a clinical-stage biopharmaceutical company dedicated to developing novel therapies for patients suffering from gastrointestinal disorders. Headquartered in Raleigh, North Carolina, the company has focused its efforts on creating effective treatments for conditions that currently lack adequate therapeutic options. Its primary product candidate, Vurolenatide, is a long-acting injectable glucagon-like peptide-1 that has advanced to Phase 3 clinical trials for the management of short bowel syndrome, a debilitating condition that significantly impacts patients' quality of life. In addition to Vurolenatide, 9 Meters Biopharma has developed a diverse pipeline of products, including NM-136, a humanized monoclonal antibody targeting obesity and related conditions; NM-102, a small molecule peptide designed to prevent antigen entry into systemic circulation; and NM-003, a proprietary glucagon-like peptide-2 receptor agonist aimed at preventing acute graft versus host disease. The company has also partnered on Larazotide, an 8-amino acid peptide that is currently in Phase 2 clinical trials for multi-system inflammatory syndrome. Despite its innovative pipeline and strategic licensing agreements with entities such as Amunix, MHS Care Innovation LLC, Alba Therapeutics Corporation, and EBRIS, 9 Meters Biopharma faced significant financial challenges, leading to a voluntary petition for liquidation under Chapter 7 of the U.S. Bankruptcy Code on July 17, 2023.
What Products and Services Does NMTRQ Offer?
- Develop therapies for rare digestive diseases and gastrointestinal disorders.
- Focus on innovative treatments for conditions with unmet medical needs.
- Conduct clinical trials to evaluate the efficacy and safety of its drug candidates.
- Engage in partnerships and licensing agreements to enhance its research capabilities.
- Target specific conditions such as short bowel syndrome, obesity, and acute graft versus host disease.
- Utilize advanced biopharmaceutical technologies to create long-acting injectable therapies.
How Does NMTRQ Make Money?
- Generate revenue through the development and commercialization of pharmaceutical products.
- Engage in licensing agreements with other biopharmaceutical companies to expand product offerings.
- Conduct clinical trials funded by partnerships and grants to support research and development.
- Focus on niche markets with high unmet medical needs to capture market share.
- Leverage intellectual property and proprietary technologies to create competitive advantages.
What Industry Does NMTRQ Operate In?
The biotechnology industry is characterized by rapid innovation and significant investment in research and development. With a growing focus on personalized medicine and targeted therapies, companies like 9 Meters Biopharma are positioned within a market that is expected to expand significantly. The global biotechnology market is projected to reach approximately $2.4 trillion by 2028, driven by advancements in drug development and increasing prevalence of chronic diseases. However, the competitive landscape is intense, with numerous players vying for market share in therapeutic areas that address unmet medical needs.
Who Are NMTRQ's Key Customers?
- Patients suffering from rare digestive diseases and gastrointestinal disorders.
- Healthcare providers seeking effective treatment options for their patients.
- Pharmaceutical partners interested in licensing or collaborating on drug development.
- Investors and stakeholders looking for innovative biopharmaceutical opportunities.
- Regulatory bodies involved in the approval and oversight of new therapies.
How 9 Meters Biopharma, Inc. Is Valued
Relative to its peer group, NMTRQ's quantitative score of 48/100 is below the peer average of 73/100.
NMTRQ Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- There's been a noticeable uptick in positive chatter within the community lately, suggesting some are seeing potential value others might be missing.
- Recent insider buying activity, even if small, could signal that those closest to the company believe in its future prospects.
- Despite the challenges, some community members are highlighting the potential of their pipeline and upcoming trial results as a possible catalyst.
- The stock's current low valuation might be attracting bargain hunters who believe the downside risk is limited.
Bear Case
- The overall sentiment remains cautious due to the company's financial struggles and past performance.
- Concerns persist about the company's ability to secure funding and continue operations without further dilution.
- Many in the community are wary of the high risk associated with biotech companies undergoing restructuring.
- Negative news and regulatory hurdles in the past have created a lingering sense of distrust among investors.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
NMTRQ Latest News
No recent news available for NMTRQ.
NMTRQ Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for NMTRQ.
Price Targets
Wall Street price target analysis for NMTRQ.
NMTRQ MoonshotScore
What does this score mean?
The MoonshotScore rates NMTRQ 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Peter H. R. Green
CEO
Peter H. R. Green has a robust background in the biopharmaceutical industry, bringing extensive experience in managing clinical-stage companies. He has held various leadership roles throughout his career, focusing on drug development and strategic partnerships. His educational background includes advanced degrees in life sciences, equipping him with the knowledge necessary to lead a biopharmaceutical firm effectively.
Track Record: Under Peter H. R. Green's leadership, 9 Meters Biopharma has developed a promising pipeline of therapeutic candidates, advancing Vurolenatide to Phase 3 clinical trials. His strategic vision has fostered partnerships that enhance the company's research capabilities, although recent financial challenges have significantly impacted the company's trajectory.
NMTRQ OTC Market Information
The OTC Other tier includes companies that do not meet the financial standards required for listing on major exchanges like NYSE or NASDAQ. This tier often features smaller companies or those undergoing financial difficulties, which can lead to less visibility and liquidity in the market.
- OTC Tier: OTC Other
- Potential for high volatility due to low trading volumes.
- Limited financial disclosures may obscure the company's true financial health.
- Increased risk of fraud or mismanagement in less regulated environments.
- Verify the company's financial statements and disclosures.
- Assess the management team's experience and track record.
- Evaluate the company's pipeline and clinical trial progress.
- Investigate any pending litigation or regulatory issues.
- Review market conditions and competitive landscape.
- Partnerships with established biopharmaceutical firms.
- Presence of a qualified management team with relevant experience.
- History of clinical trial advancements and regulatory submissions.
NMTRQ Healthcare Stock FAQ
What does the AI Score mean for NMTRQ?
NMTRQ holds an AI Score of 48/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. 9 Meters Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for rare digestive diseases and gastrointestinal disorders. The company has advanced its lead …
What does 9 Meters Biopharma, Inc. do?
9 Meters Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for rare digestive diseases and gastrointestinal disorders. The company's lead product candidate, Vurolenatide, is in Phase 3 clinical trials for short bowel syndrome, while its pipeline includes other candidates targeting obesity and acute graft versus host disease.
What are the main risks for NMTRQ?
The main risks for 9 Meters Biopharma, Inc. include ongoing financial instability due to its recent bankruptcy filing, which raises concerns about its operational viability. Additionally, the company faces potential regulatory hurdles that could delay or prevent the approval of its drug candidates, as well as high competition in the biotechnology sector that may hinder its market penetration.
How does 9 Meters Biopharma, Inc. navigate regulatory approval processes?
9 Meters Biopharma, Inc. follows a structured approach to navigate regulatory approval processes, focusing on compliance with FDA guidelines during clinical trials. The company submits detailed data from its trials to demonstrate the safety and efficacy of its products. Successful navigation of these processes is critical for gaining market access and ensuring that its therapies can reach patients in need.
What are the key factors to evaluate for NMTRQ?
9 Meters Biopharma, Inc. (NMTRQ) holds an AI score of 48/100 (low). Not financial advice.
How frequently does NMTRQ data refresh on this page?
NMTRQ's price was last updated on Jul 20, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven NMTRQ's recent stock price performance?
9 Meters Biopharma, Inc. (NMTRQ) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative pipeline with multiple drug candidates targeting rare diseases. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider NMTRQ overvalued or undervalued right now?
9 Meters Biopharma, Inc. (NMTRQ) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research NMTRQ before investing?
Before investing in 9 Meters Biopharma, Inc. (NMTRQ), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Company is undergoing bankruptcy proceedings, which may affect the accuracy and completeness of information.